• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

    6/26/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email

    NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing.

    REGISTER AND VIEW PRESENTATIONS HERE

    Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here.

    The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.

    Presenting Companies

    CompanyTicker(s)
    MetaVia Inc.(NASDAQ:MTVA)
    Nasus Pharma Ltd.(NYSE:NSRX)
    CytoSorbents Corporation(NASDAQ:CTSO)
    PetVivo Holdings Inc.(OTCQX:PETV)
    Jaguar Health, Inc.(NASDAQ:JAGX)
    Reviva Pharmaceuticals Holdings, Inc.(OTCQB:RVPH)
    Zivo Bioscience, Inc.(OTCID: ZIVO)
    4DMedical Limited(OTC:FDMDF, ASX: 4DX))
    Abingdon Health plc(OTCQB:ABDXF, LSE: ABDX))
    Innovotech, Inc.(OTCQB:IOTCF, TSXV:IOT)
    Lakewood-Amedex Biotherapeutics Inc.(NASDAQ:LABT)
    Kelyniam Global, Inc.(OTCID: KLYG)
    IMUNON, Inc.(NASDAQ:IMNN)
    Promino Nutritional Sciences Inc.((OTCID: MUSLF, CSE:MUSL)
    Envoy Medical Inc.(NASDAQ:COCH)
    Coiled Therapeutics plc(OTCQB:COTXF, AIM: COIL))
    Aspire Biopharma Holdings Inc.(NASDAQ:ASBP)
    Rocket Doctor AI Inc.(OTCQB:AIRDF, CSE:AIDR)
    Phio Pharmaceuticals Corp.(NASDAQ:PHIO)
    aTyr Pharma, Inc.(NASDAQ:ATYR)
    NuFarm Ltd.(OTC:NUFMF, ASX: NUF))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    Greg Young


    VP Corporate Services


    OTC Markets Group


    (212) 652-5958


    greg@otcmarkets.com



    Primary Logo

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA
    $NSRX
    $CTSO
    $PETV

    CompanyDatePrice TargetRatingAnalyst
    Envoy Medical Inc.
    $COCH
    3/31/2026$2.50Buy
    H.C. Wainwright
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    aTyr Pharma Inc.
    $ATYR
    9/16/2025$1.50Outperform → Sector Perform
    RBC Capital Mkts
    aTyr Pharma Inc.
    $ATYR
    9/15/2025$1.00Overweight → Equal Weight
    Wells Fargo
    aTyr Pharma Inc.
    $ATYR
    9/15/2025Buy → Neutral
    H.C. Wainwright
    aTyr Pharma Inc.
    $ATYR
    9/15/2025$1.00Outperform → Market Perform
    Leerink Partners
    aTyr Pharma Inc.
    $ATYR
    9/15/2025Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Tardugno Michael H was granted 4,603 shares, increasing direct ownership by 7% to 68,999 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    7/21/26 4:17:03 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel and Corp Sec Eylward Susan was granted 2,150 shares and sold $3,830 worth of shares (2,150 units at $1.78) (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    7/21/26 4:15:47 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Faller Douglas Vincent was granted 3,082 shares, increasing direct ownership by 13% to 26,286 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    7/21/26 4:15:06 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session. This release corrects the day of the week that the presentation will be hel

    7/22/26 12:30:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

    Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance.SARASOTA, Fla., July 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced resistance data for Nu-3 in alignment with the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB).

    7/22/26 8:02:00 AM ET
    $LABT

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session."We look forward to engaging with investors at the Renmark Financial Virtual

    7/22/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $9,900 worth of shares (10,000 units at $0.99), increasing direct ownership by 2% to 421,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/29/26 4:02:13 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    6/22/26 7:12:42 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mariani Peter J bought $44,000 worth of shares (100,000 units at $0.44), increasing direct ownership by 19% to 638,113 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    6/16/26 7:00:14 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    SEC Filings

    View All

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    7/21/26 7:07:31 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    7/20/26 5:20:17 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Jaguar Health Inc.

    S-1 - Jaguar Health, Inc. (0001585608) (Filer)

    7/15/26 5:37:04 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

    Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation. He has played a signific

    7/21/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET. This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast wi

    6/17/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

    POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, effective as of June 5, 2026. In connection with their appointment to the Board of Directors, Mr. Sonenreich has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee, Ms. Hannaway has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Commit

    6/9/26 7:00:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    11/14/24 6:51:17 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Financials

    Live finance-specific insights

    View All

    CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

    PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Healt

    7/20/26 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Financial and Operational Results for Fiscal 2026

    MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported operational results for the fourth quarter of its fiscal year ended March 31, 2026, and financial results for the full fiscal year. PetVivo will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q4 Operational Highlights

    6/29/26 5:30:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026

    MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will report financial results for the year ending March 31, 2026, on Monday, June 29, 2026 after market close. The company will host a conference call to discuss these results at 5:00 p.m. CT (6:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor

    6/25/26 4:04:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care